Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Subscribe
Biotech
Cell & Gene Therapy
Clinical Data
Venture Capital
Deals
Research
Medtech
Devices
Diagnostics
AI and Machine Learning
CRO
Special Reports
Fierce 50
Special Report
Awards Gala
Resources
Fierce Events
Industry Events
Webinars
Podcasts
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
heart attack
Biotech
Idorsia bags $350M upfront from Viatris for 2 late-phase assets
Weeks from the end of its cash runway, Idorsia has secured $350 million upfront from Viatris in exchange for the global rights to two phase 3 assets.
Nick Paul Taylor
Feb 28, 2024 7:56am
CSL's largest ph. 3 trial ends in failure for heart attack drug
Feb 12, 2024 5:21am
QuidelOrtho faces Class I recall of heart attack blood tests
Jul 17, 2023 11:46am
Scientists pinpoint location of plaque ruptures
Jun 6, 2023 7:35am
Cleerly scores $192M for heart attack-predicting AI
Jul 25, 2022 11:51am
Novartis, Medtronic to support digital heart disease startups
Jul 5, 2022 12:34pm